Double-blind, randomized, placebo-controlled clinical trials with non-prescription medications for the treatment of obesity

Obesity Research

Volumn 7, Issue 4, 1999, Pages 370-378

  Greenway, Frank ^a   Heber, David ^b   Raum, William ^c   Morales, Silvia ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b UCLA MEDICAL CENTER   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Benzocaine; Blood pressure; Phenylpropanolamine; Pseudoephedrine; Weight loss

Indexed keywords

ANOREXIGENIC AGENT; BENZOCAINE; EPHEDRINE; NON PRESCRIPTION DRUG; PHENYLPROPANOLAMINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FEMALE; HUMAN; MALE; MIDDLE AGED; OBESITY; RANDOMIZED CONTROLLED TRIAL; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; APPETITE DEPRESSANTS; BENZOCAINE; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DRUGS, NON-PRESCRIPTION; EPHEDRINE; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; PHENYLPROPANOLAMINE; WEIGHT LOSS;

EID: 0033158562     PISSN: 10717323     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1550-8528.1999.tb00420.x     Document Type: Article

References (9)

1. Morgan JP. Phenylpropanolamine: A Critical Analysis of Reported Adverse Reactions and Overdosage. Fort Lee, NJ: Jack K. Burgess, Inc.; 1986;3-10.
2. Weintraub M. Phenylpropanolamine as an anorexiant agent in weight control: a review of published and unpublished studies. In: Morgan JP, Kagan DV, Brody JS, eds. Phenylpropanolamine: Risks, Benefits, and Controversies. Clinical Pharmacology and Therapeutics, Vol. 5. New York: Praeger Publishers; 1985;53-79.
3. Bray GA. The obese patient. In: Smith LH, jr., ed. Major Problems in Internal Medicine. Philadelphia: W.B. Saunders Co.; 1976;9:1-450.
4. Arch JR. Thermogenic and anorectic effects of ephedrine and congeners in mice and rats. Life Sci. 1982;30:1817-26.
5. Plotz M. Obesity. Med Times. 1958;86:860-3.
6. Gould WL. Obesity and hypertension: the importance of a safe compound to control appetite. North Carolina Med J. 1950;11:327-34.
7. McClure CW, Brusch CA. Treatment of oral syndrome obesity with non-traditional appetite control plan. J Am Med Womens Assoc. 1973;28:239-48.
8. Wellman PJ, Davies BT. Reversal of cirazoline- and phenylpropanolamine-induced anorexia by the alpha 1-receptor antagonist prazosin. Pharmacol Biochem Behav. 1992;42:97-100.
9. Weintraub M, Sundarsesan PR, Schuster B, et al. Long-term weight control: The National Heart, Lung and Blood Institute funded multimodel intervention study. I-VII. Clin Pharmacol Ther. 1992;51:581-646.